We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
10
Research Clients
320
Reports published
10k+
Readers in database
FRESCO-2 data at #ESMO22 showed 2.6m OS benefit for #fruquintinib in heavily pretreated pts, comparing favourably with other agents in >3L #mCRC. Data support filings ex-China & further dev in other settings & as part of combos. For more on @hutchmed: https://www.trinitydelta.org/companies/hutchmed/
Our post interims Update note on @arecor_plc incorporates the recent @TetrisPharma acquisition. Key events for the #diabetes franchise during H2 include #AT247 P1 pump data & start of the next trial with #AT278.
For more on #AREC $AREC see:
https://www.trinitydelta.org/companies/arecor-therapeutics/
Interesting updates from #FutureMedical’s 1H include 1st EU MED3000 orders from partner Cooper & in the US a partner is being sought with inquiries received. US filing on track for end-Sept for potential authorisation in Q123. For more on $FUM see:
https://www.trinitydelta.org/companies/futura-medical/
Interims confirm cont progress at @arecor_plc. Key events for the #diabetes franchise on track for H2: #AT247 P1 data & #AT278 next trial. @TetrisPharma M&A the major post period highlight & integration is going well. For more on #AREC $AREC see:
https://www.trinitydelta.org/companies/arecor-therapeutics/
Review of @HUTCHMED’s pipeline to support China & Global ambitions; 1st wave marketed in China & in reg trials ex-China; 2nd wave focused on haem-onc. Important details on positive #fruquintinib FRESCO-2 data at #ESMO22 on 12 Sep. Read our $HCM Update:
https://www.trinitydelta.org/companies/hutchmed/
FY22 core rev guidance upgrade to 30% on robust demand.@MaxCyte_info strategic investment continues in support of pre-launch customer scale up. Our $MXCT Q222 Update outlines SPL progress/catalysts & focuses on $CRSP $VRTX #sicklecell #genetherapy exa-cel: https://www.trinitydelta.org/companies/maxcyte/
Please sign up here to be added to our distribution database
;